These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14584799)

  • 1. Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as corticotropin releasing hormone type 1 antagonists.
    McCluskey A; Keller PA; Morgan J; Garner J
    Org Biomol Chem; 2003 Oct; 1(19):3353-61. PubMed ID: 14584799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists.
    Wustrow DJ; Capiris T; Rubin R; Knobelsdorf JA; Akunne H; Davis MD; MacKenzie R; Pugsley TA; Zoski KT; Heffner TG; Wise LD
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2067-70. PubMed ID: 9873487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.
    Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Nemeth GA; Arvanitis A; Cheeseman RS; Chorvat RJ; Ciganek E; Christos TE; Gilligan PJ; Krenitsky P; Scholfield E; Strucely P
    J Med Chem; 1999 Mar; 42(5):819-32. PubMed ID: 10072680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptor.
    Webb TR; Moran T; Huang CQ; McCarthy JR; Grigoriadis DE; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3869-73. PubMed ID: 15225687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala.
    Bakshi VP; Smith-Roe S; Newman SM; Grigoriadis DE; Kalin NH
    J Neurosci; 2002 Apr; 22(7):2926-35. PubMed ID: 11923457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility.
    Chen C; Wilcoxen KM; Huang CQ; McCarthy JR; Chen T; Grigoriadis DE
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3669-73. PubMed ID: 15203140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y; Liao Q; Wei J; Gao Q
    Neurochem Int; 2010 Jan; 56(1):107-17. PubMed ID: 19782115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.
    Yuan J; Gulianello M; De Lombaert S; Brodbeck R; Kieltyka A; Hodgetts KJ
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2133-6. PubMed ID: 12127521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.
    Chen C; Dagnino R; De Souza EB; Grigoriadis DE; Huang CQ; Kim KI; Liu Z; Moran T; Webb TR; Whitten JP; Xie YF; McCarthy JR
    J Med Chem; 1996 Oct; 39(22):4358-60. PubMed ID: 8893829
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists.
    Gilligan PJ; He L; Culp S; Fitzgerald L; Tam SW; Wong YN
    Bioorg Med Chem; 1999 Nov; 7(11):2321-8. PubMed ID: 10632042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists.
    Cocuzza AJ; Hobbs FW; Arnold CR; Chidester DR; Yarem JA; Culp S; Fitzgerald L; Gilligan PJ
    Bioorg Med Chem Lett; 1999 Apr; 9(7):1057-62. PubMed ID: 10230640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heteroaryl-substituted 4-(1H-pyrazol-1-yl)-5,6-dihydro-1H-pyrrolo[2,3-d]pyrimidine derivatives as potent and selective corticotropin-releasing factor receptor-1 antagonists.
    Sabbatini FM; Di Fabio R; St-Denis Y; Capelli AM; Castiglioni E; Contini S; Donati D; Fazzolari E; Gentile G; Micheli F; Pavone F; Rinaldi M; Pasquarello A; Zampori MG; Di Felice P; Zarantonello P; Arban R; Perini B; Vitulli G; Benedetti R; Oliosi B; Worby A
    ChemMedChem; 2008 Feb; 3(2):226-9. PubMed ID: 18000940
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
    Kuppast B; Spyridaki K; Liapakis G; Fahmy H
    Eur J Med Chem; 2014 May; 78():1-9. PubMed ID: 24675175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
    Arvanitis AG; Gilligan PJ; Chorvat RJ; Cheeseman RS; Christos TE; Bakthavatchalam R; Beck JP; Cocuzza AJ; Hobbs FW; Wilde RG; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky PJ; Rescinito JP; Scholfield E; Culp S; De Souza EB; Fitzgerald L; Grigoriadis D; Tam SW; Shen HL
    J Med Chem; 1999 Mar; 42(5):805-18. PubMed ID: 10072679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential uses of corticotropin-releasing hormone antagonists.
    Zoumakis E; Rice KC; Gold PW; Chrousos GP
    Ann N Y Acad Sci; 2006 Nov; 1083():239-51. PubMed ID: 17148743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).
    Islam MR; Markatos C; Pirmettis I; Papadopoulos M; Karageorgos V; Liapakis G; Fahmy H
    Molecules; 2024 Aug; 29(15):. PubMed ID: 39125051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-affinity relationships of 4-(5-Aryl-1,2,3,6-tetrahydropyridino)pyrimidine derivatives as corticotropin-releasing factor(1) receptor antagonists.
    Kumagai T; Okubo T; Kataoka-Okubo H; Chaki S; Okuyama S; Nakazato A
    Bioorg Med Chem; 2001 May; 9(5):1349-55. PubMed ID: 11377192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.